ATE207747T1 - Verwendung von vincristin zur auswertung von wirkstoffen in zentralnervensystems - Google Patents
Verwendung von vincristin zur auswertung von wirkstoffen in zentralnervensystemsInfo
- Publication number
- ATE207747T1 ATE207747T1 AT94403014T AT94403014T ATE207747T1 AT E207747 T1 ATE207747 T1 AT E207747T1 AT 94403014 T AT94403014 T AT 94403014T AT 94403014 T AT94403014 T AT 94403014T AT E207747 T1 ATE207747 T1 AT E207747T1
- Authority
- AT
- Austria
- Prior art keywords
- evaluation
- vincristin
- active ingredients
- nervous system
- central nervous
- Prior art date
Links
- 238000011156 evaluation Methods 0.000 title abstract 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 title abstract 2
- 229960004528 vincristine Drugs 0.000 title abstract 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 title 1
- 230000001537 neural effect Effects 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 238000010171 animal model Methods 0.000 abstract 1
- 238000010876 biochemical test Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000877 morphologic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9006399A FR2662355B1 (fr) | 1990-05-22 | 1990-05-22 | Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE207747T1 true ATE207747T1 (de) | 2001-11-15 |
Family
ID=9396855
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94403014T ATE207747T1 (de) | 1990-05-22 | 1991-05-21 | Verwendung von vincristin zur auswertung von wirkstoffen in zentralnervensystems |
| AT91401311T ATE132369T1 (de) | 1990-05-22 | 1991-05-21 | Verwendung von 1-(2-naphthylethyl)-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridi zur herstellung eines medikaments zur behandlung von zerebralen und neuronalen krankheiten |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT91401311T ATE132369T1 (de) | 1990-05-22 | 1991-05-21 | Verwendung von 1-(2-naphthylethyl)-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridi zur herstellung eines medikaments zur behandlung von zerebralen und neuronalen krankheiten |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US5229389A (de) |
| EP (2) | EP0458696B1 (de) |
| JP (2) | JP2618115B2 (de) |
| KR (1) | KR0181330B1 (de) |
| AT (2) | ATE207747T1 (de) |
| BR (1) | BR9105015A (de) |
| CA (2) | CA2042974C (de) |
| CY (1) | CY2283B1 (de) |
| DE (2) | DE69132797T2 (de) |
| DK (2) | DK0655247T3 (de) |
| FR (1) | FR2662355B1 (de) |
| HK (1) | HK1001471A1 (de) |
| HU (1) | HU208922B (de) |
| IE (1) | IE911707A1 (de) |
| IL (3) | IL98175A (de) |
| TW (1) | TW216771B (de) |
| ZA (1) | ZA913865B (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0192386A (ja) * | 1987-10-05 | 1989-04-11 | Hitachi Ltd | 密閉循環型吸収式冷凍機及び吸収式冷凍機用吸収液 |
| FR2662355B1 (fr) * | 1990-05-22 | 1994-11-10 | Sanofi Sa | Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux. |
| FR2662442A1 (fr) * | 1990-05-23 | 1991-11-29 | Midy Spa | Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant. |
| US5618822A (en) * | 1990-05-23 | 1997-04-08 | Sanofi | N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them |
| US5557209A (en) * | 1990-12-20 | 1996-09-17 | Hewlett-Packard Company | Identification of pin-open faults by capacitive coupling through the integrated circuit package |
| FR2672213B1 (fr) | 1991-02-05 | 1995-03-10 | Sanofi Sa | Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres. |
| FR2690158B1 (fr) * | 1992-04-17 | 1994-07-22 | Sanofi Elf | Nouveau derive arylpiperidinique, procede pour sa preparation et compositions pharmaceutiques le contenant. |
| FR2702656B1 (fr) * | 1993-03-18 | 1995-06-16 | Sanofi Elf | Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs. |
| US5698565A (en) * | 1995-06-09 | 1997-12-16 | Hoffmann-La Roche Inc. | Use of phenoxy-pyridine derivatives |
| FR2736053B1 (fr) * | 1995-06-28 | 1997-09-19 | Sanofi Sa | Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines |
| UA57004C2 (uk) * | 1995-10-26 | 2003-06-16 | Санофі - Сінтелябо | Лікувальний засіб, що містить 1-(2-нафт-2-ілетил)-4-(3-трифторметилфеніл)-1,2,3,6,-тетрагідропіридин (варіанти), та спосіб лікування бічного аміотрофічного склерозу |
| FR2740343B1 (fr) * | 1995-10-26 | 1999-01-22 | Sanofi Sa | Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique |
| AU719038B2 (en) * | 1996-03-29 | 2000-05-04 | Trustees Of Boston University | Methods for diagnosing and treating Alzheimer's disease |
| US5891465A (en) * | 1996-05-14 | 1999-04-06 | Biozone Laboratories, Inc. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
| FR2757160B1 (fr) * | 1996-12-13 | 1999-03-12 | Sanofi Sa | 1-phenylalkyl-1,2,3,6-tetrahydropyridines |
| FR2757161B1 (fr) * | 1996-12-13 | 1999-03-12 | Sanofi Sa | Diphenylalkyl-tetrahydropyridines |
| FR2757510B1 (fr) * | 1996-12-23 | 2000-01-07 | Sanofi Sa | Forme microparticulaire d'un derive de tetrahydropyridine |
| FR2757512B1 (fr) * | 1996-12-24 | 1999-03-12 | Sanofi Sa | Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines |
| JP2001511141A (ja) * | 1997-02-03 | 2001-08-07 | サノフィ−サンテラボ | 1−[4−(3−トリフルオロメチルフェニル)−1,2,3,6−テトラヒドロピリド−1−イル]−2−(6,7−ジメトキシナフト−2−イル)エタンの、脳障害および神経障害を治療する目的の薬剤を調製するための使用 |
| FR2762514B1 (fr) | 1997-04-29 | 1999-10-22 | Sanofi Sa | Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation |
| FR2763847B1 (fr) * | 1997-05-28 | 2003-06-06 | Sanofi Sa | Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1 |
| CO4980891A1 (es) * | 1997-11-14 | 2000-11-27 | Sanofi Sa | Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer |
| FR2771007B1 (fr) * | 1997-11-14 | 2000-12-01 | Sanofi Sa | Association de principes actifs pour le traitement de la demence senile du type alzheimer |
| DE19751949A1 (de) * | 1997-11-24 | 1999-05-27 | Bayer Ag | Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration |
| TWI237035B (en) * | 1998-07-24 | 2005-08-01 | Polyplastics Co | Polyacetal copolymer |
| CN102727501A (zh) * | 2002-03-27 | 2012-10-17 | 菲特法姆股份有限公司 | 皂角苷配基及其衍生物的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2531707A1 (fr) * | 1982-08-16 | 1984-02-17 | Midy Spa | Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques |
| FR2639226B1 (fr) * | 1988-11-18 | 1993-11-05 | Sanofi | Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs |
| FR2662355B1 (fr) * | 1990-05-22 | 1994-11-10 | Sanofi Sa | Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux. |
-
1990
- 1990-05-22 FR FR9006399A patent/FR2662355B1/fr not_active Expired - Lifetime
-
1991
- 1991-05-17 IL IL9817591A patent/IL98175A/en not_active IP Right Cessation
- 1991-05-17 IL IL11216791A patent/IL112167A/en not_active IP Right Cessation
- 1991-05-20 IE IE170791A patent/IE911707A1/en not_active IP Right Cessation
- 1991-05-20 TW TW080103889A patent/TW216771B/zh not_active IP Right Cessation
- 1991-05-21 CA CA002042974A patent/CA2042974C/en not_active Expired - Lifetime
- 1991-05-21 US US07/703,835 patent/US5229389A/en not_active Expired - Lifetime
- 1991-05-21 EP EP91401311A patent/EP0458696B1/de not_active Expired - Lifetime
- 1991-05-21 AT AT94403014T patent/ATE207747T1/de not_active IP Right Cessation
- 1991-05-21 DK DK94403014T patent/DK0655247T3/da active
- 1991-05-21 DE DE69132797T patent/DE69132797T2/de not_active Expired - Fee Related
- 1991-05-21 AT AT91401311T patent/ATE132369T1/de not_active IP Right Cessation
- 1991-05-21 DE DE69115989T patent/DE69115989T2/de not_active Expired - Lifetime
- 1991-05-21 DK DK91401311.5T patent/DK0458696T3/da active
- 1991-05-21 EP EP94403014A patent/EP0655247B1/de not_active Expired - Lifetime
- 1991-05-21 CA CA002365832A patent/CA2365832C/en not_active Expired - Fee Related
- 1991-05-22 JP JP3146949A patent/JP2618115B2/ja not_active Expired - Lifetime
- 1991-05-22 KR KR1019910008272A patent/KR0181330B1/ko not_active Expired - Lifetime
- 1991-05-22 ZA ZA913865A patent/ZA913865B/xx unknown
- 1991-05-22 HU HU911729A patent/HU208922B/hu unknown
- 1991-11-07 US US07/789,044 patent/US5270320A/en not_active Expired - Lifetime
- 1991-11-19 BR BR919105015A patent/BR9105015A/pt not_active Application Discontinuation
-
1993
- 1993-10-20 US US08/142,069 patent/US5468753A/en not_active Expired - Lifetime
-
1994
- 1994-12-27 IL IL11216794A patent/IL112167A0/xx unknown
-
1996
- 1996-08-20 JP JP8218926A patent/JP2954029B2/ja not_active Expired - Fee Related
-
1998
- 1998-01-20 HK HK98100449A patent/HK1001471A1/xx not_active IP Right Cessation
-
2002
- 2002-05-15 CY CY0200037A patent/CY2283B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69132797D1 (de) | Verwendung von Vincristin zur Auswertung von Wirkstoffen in Zentralnervensystems | |
| DE69100547D1 (de) | Methode und Vorrichtung zum elektrochemischen Bearbeiten der Spritzöffnungen von Brennstoff-Einspritzdüsen. | |
| DE69128362D1 (de) | Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit | |
| AT368656B (de) | Optisch auslesbarer scheibenfoermiger aufzeichnungstraeger, verfahren zu dessen herstellung und vorrichtung zur durchfuehrung dieses verfahrens | |
| DE3577564D1 (de) | Polymere zur verwendung als hilfsmittel in der filtrationskontrolle fuer bohrfluessigkeiten. | |
| DE3780691D1 (de) | Methode und geraet zur regelung des kraftstoffeinspritzzeitpunkts und der kraftstoffeinspritzmenge. | |
| DE3882058D1 (de) | Immunoreaktives reagens, verfahren zu seiner herstellung und seine verwendung zur bestimmung einer immunoreaktiven spezies. | |
| DE3763289D1 (de) | Ultrafiltrations-, hyperfiltrations- oder entmineralisierungselement, verfahren zu seiner herstellung und seine verwendung zur aufbereitung von fluessigen, radioaktiven abfaellen. | |
| DE3764056D1 (de) | Verfahren und vorrichtung zur aufzeichnung und/oder auswertung des bewegungsverhaltens von versuchstieren. | |
| DE3885761D1 (de) | Verfahren, anwendung desselben und vorrichtung zur lambdawerterfassung. | |
| DE3485319D1 (de) | Rekombinante dns, diese rekombinante dns enthaltende bakterien, und verfahren zur herstellung von l-threonin oder l-isoleucin unter verwendung dieser bakterien. | |
| DE3687064D1 (de) | Verfahren zur identifizierung von mit gesteigerter diabetesgefahr assoziierten allelen. | |
| Rickson et al. | Social bases of farmers' responses to land degradation. | |
| AT383491B (de) | Vorrichtung zum verabreichen von voll- oder sitz- baedern, insbesondere unter verwendung von peloid | |
| DE59000468D1 (de) | Verfahren zur schnellen pruefung der wirksamkeit von agenzien auf mikroorganismen. | |
| DE3852345D1 (de) | Methode zur Messung von Impuls-Parametern. | |
| AT386230B (de) | Verfahren und vorrichtung zur herstellung von holzschliff | |
| DE3865794D1 (de) | Hydroraffinationskatalysator, ausgehend von hydrogelen, verfahren zur herstellung und verwendung. | |
| DE3865649D1 (de) | Apatitfuellmaterial zur fluessigchromatografie und verfahren zu seiner herstellung. | |
| AT360448B (de) | Verfahren und anordnung zur behandlung von fluessigkeiten, insbesondere abwasser, unter verwendung von aerobischer reinigung | |
| ATE9343T1 (de) | 2,6-diethyl-3,5-dimethyl-2,3-dihydro-4h-pyran, verfahren zu seiner herstellung und seine verwendung zur frueherkennung, lokalisierung und bekaempfung von lasioderma serricorne f. | |
| ATA369880A (de) | Verfahren zur erhoehung der standfestigkeit von plastischem, tonig-schluffrigem gebirge und vorrichtung zur durchfuehrung des verfahrens | |
| DE3773331D1 (de) | Optisch aktives propanon-derivat, verfahren zu seiner herstellung und seine verwendung. | |
| ATA77785A (de) | Pruefmodell zur verwendung in sterilisiergeraeten, insbesondere beim sterilisieren von biologische stoffe enthaltendem sterilisiergut | |
| ATA124192A (de) | Verfahren zur bestimmung, quantifizierung und/oder ojektivierung von geruchsimmissionen, anordnung zur durchführung des verfahrens und verwendung desselben |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |